ZAI LAB LTD: CITIGROUP LOWERS TARGET PRICE FROM $58 TO $53
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy ZLAB?
Source: moomoo
- Company Announcement: Zailab Ltd. has announced a reduction in its target price.
- New Target Price: The target price has been cut from $58 to $53.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZLAB
Wall Street analysts forecast ZLAB stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.720
Low
25.70
Averages
47.93
High
74.00
Current: 17.720
Low
25.70
Averages
47.93
High
74.00
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zai Lab's Q4 2025 Earnings Call Highlights Global Innovation and Pipeline Progress
- Significant Revenue Growth: Zai Lab reported total revenue of $127.6 million in Q4 2025, a 17% year-over-year increase, with full-year revenue reaching $460.2 million, up 15%, demonstrating strong performance driven by contributions from XACDURO and NUZYRA.
- Rapid R&D Progress: Zoci showed an 80% objective response rate in untreated brain metastases patients with a favorable safety profile, with management emphasizing its advancement to global Phase III trials within two years, targeting U.S. approval by 2028, marking a significant breakthrough in oncology.
- Strategic Transition Year: Management views 2026 as a transition year focused on execution and upcoming launches, and while full-year financial guidance was not provided, the expectation is to leverage a robust pipeline and strong cash position to drive long-term growth, reflecting confidence in future market opportunities.
- Effective Cost Control: R&D expenses declined by 6% for the full year, while SG&A expenses decreased by 12% in Q4, leading to a 19% improvement in operating loss to $229.4 million, showcasing the company's success in enhancing operational leverage and financial flexibility, strengthening its position in a competitive market.
See More
Zai Lab Scheduled to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Zai Lab (ZLAB) is set to announce its Q4 2023 earnings on February 26 before market open, drawing increased attention from investors amid a competitive biopharmaceutical landscape.
- Earnings Expectations: The consensus EPS estimate stands at -$0.42, reflecting a 47.5% year-over-year improvement, indicating some progress in the company's efforts to enhance profitability despite remaining in the red.
- Revenue Expectations: The consensus revenue estimate is $122.67 million, representing a 12.4% year-over-year increase, highlighting Zai Lab's potential for sales growth as market demand recovers.
- Estimate Revisions: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have faced five downward revisions with no upward changes, suggesting analysts' cautious outlook on the company's future performance.
See More
ZAI LAB LTD: CITIGROUP LOWERS TARGET PRICE FROM $58 TO $53
- Company Announcement: Zailab Ltd. has announced a reduction in its target price.
- New Target Price: The target price has been cut from $58 to $53.
See More
Oncolytics Biotech Receives FDA Fast Track Designation
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer, which is expected to expedite the approval process and enhance market competitiveness.
- Clinical Data Advantage: The 33% response rate of pelareorep combined with standard chemotherapy significantly surpasses the 10% rate of chemotherapy alone, with a median survival of 27 months, indicating its potential value in hard-to-treat cancer populations.
- Significant Market Opportunity: The annual revenue for second-line treatment of KRAS-mutant colorectal cancer ranges between $3 billion and $5 billion, positioning Oncolytics' innovative therapy to capture a substantial share in this rapidly growing market.
- Team Expansion and Strategic Positioning: Oncolytics Biotech has recently appointed two executives to support its expansion plans, demonstrating the company's commitment to future clinical trials and market outreach, thereby strengthening its leadership position in the biotech sector.
See More
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
- Regulatory Acceleration: In 2025, the FDA approved over 50 oncology drugs, with a notable shift towards targeted therapies for high-unmet-need solid tumors in 2026, projecting a market opportunity of $326.82 billion by 2031, indicating robust commercial potential.
- Fast Track Designation: Oncolytics Biotech's pelareorep received FDA Fast Track Designation for KRAS-mutant colorectal cancer, showing a 33% response rate when combined with standard chemotherapy, significantly higher than the 10% with chemotherapy alone, which will expedite its approval process.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study comparing pelareorep with standard care in March 2026, with interim data expected by year-end, providing crucial clinical evidence in a competitive market.
- Team Expansion: Oncolytics Biotech recently appointed two key executives to enhance its strategic and operational capabilities, supporting its expanding R&D projects, reflecting the company's confidence and preparedness for future growth.
See More
ClearBridge International Growth Strategy Underperforms in Q4 2025
- Quarterly Performance Review: The ClearBridge International Growth Strategy underperformed its primary MSCI EAFE benchmark in Q4 2025, indicating vulnerability in the portfolio amidst market fluctuations, which may affect investor confidence.
- Portfolio Adjustments: The strategy exited positions in Zai Lab, UniCredit, and Linde during the quarter while repurchasing EssilorLuxottica, Galderma Group, and Ryanair, demonstrating management's sensitivity to market dynamics and adaptability.
- New and Closed Positions: The fund initiated positions in Sandvik and Mettler-Toledo while closing several positions including Mitsubishi Heavy Industries, Givaudan, and Lenovo, reflecting a reassessment of future market opportunities.
- Sales Dynamics: Trane Technologies was among the larger sales in the portfolio, potentially indicating a cautious outlook on the company's future growth prospects, thereby influencing the overall direction of the investment strategy.
See More
Zai Lab's Q4 2025 Earnings Call Highlights Global Innovation and Pipeline Progress
- Significant Revenue Growth: Zai Lab reported total revenue of $127.6 million in Q4 2025, a 17% year-over-year increase, with full-year revenue reaching $460.2 million, up 15%, demonstrating strong performance driven by contributions from XACDURO and NUZYRA.
- Rapid R&D Progress: Zoci showed an 80% objective response rate in untreated brain metastases patients with a favorable safety profile, with management emphasizing its advancement to global Phase III trials within two years, targeting U.S. approval by 2028, marking a significant breakthrough in oncology.
- Strategic Transition Year: Management views 2026 as a transition year focused on execution and upcoming launches, and while full-year financial guidance was not provided, the expectation is to leverage a robust pipeline and strong cash position to drive long-term growth, reflecting confidence in future market opportunities.
- Effective Cost Control: R&D expenses declined by 6% for the full year, while SG&A expenses decreased by 12% in Q4, leading to a 19% improvement in operating loss to $229.4 million, showcasing the company's success in enhancing operational leverage and financial flexibility, strengthening its position in a competitive market.
See More
Zai Lab Scheduled to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Zai Lab (ZLAB) is set to announce its Q4 2023 earnings on February 26 before market open, drawing increased attention from investors amid a competitive biopharmaceutical landscape.
- Earnings Expectations: The consensus EPS estimate stands at -$0.42, reflecting a 47.5% year-over-year improvement, indicating some progress in the company's efforts to enhance profitability despite remaining in the red.
- Revenue Expectations: The consensus revenue estimate is $122.67 million, representing a 12.4% year-over-year increase, highlighting Zai Lab's potential for sales growth as market demand recovers.
- Estimate Revisions: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have faced five downward revisions with no upward changes, suggesting analysts' cautious outlook on the company's future performance.
See More
ZAI LAB LTD: CITIGROUP LOWERS TARGET PRICE FROM $58 TO $53
- Company Announcement: Zailab Ltd. has announced a reduction in its target price.
- New Target Price: The target price has been cut from $58 to $53.
See More
Oncolytics Biotech Receives FDA Fast Track Designation
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer, which is expected to expedite the approval process and enhance market competitiveness.
- Clinical Data Advantage: The 33% response rate of pelareorep combined with standard chemotherapy significantly surpasses the 10% rate of chemotherapy alone, with a median survival of 27 months, indicating its potential value in hard-to-treat cancer populations.
- Significant Market Opportunity: The annual revenue for second-line treatment of KRAS-mutant colorectal cancer ranges between $3 billion and $5 billion, positioning Oncolytics' innovative therapy to capture a substantial share in this rapidly growing market.
- Team Expansion and Strategic Positioning: Oncolytics Biotech has recently appointed two executives to support its expansion plans, demonstrating the company's commitment to future clinical trials and market outreach, thereby strengthening its leadership position in the biotech sector.
See More
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
- Regulatory Acceleration: In 2025, the FDA approved over 50 oncology drugs, with a notable shift towards targeted therapies for high-unmet-need solid tumors in 2026, projecting a market opportunity of $326.82 billion by 2031, indicating robust commercial potential.
- Fast Track Designation: Oncolytics Biotech's pelareorep received FDA Fast Track Designation for KRAS-mutant colorectal cancer, showing a 33% response rate when combined with standard chemotherapy, significantly higher than the 10% with chemotherapy alone, which will expedite its approval process.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study comparing pelareorep with standard care in March 2026, with interim data expected by year-end, providing crucial clinical evidence in a competitive market.
- Team Expansion: Oncolytics Biotech recently appointed two key executives to enhance its strategic and operational capabilities, supporting its expanding R&D projects, reflecting the company's confidence and preparedness for future growth.
See More
ClearBridge International Growth Strategy Underperforms in Q4 2025
- Quarterly Performance Review: The ClearBridge International Growth Strategy underperformed its primary MSCI EAFE benchmark in Q4 2025, indicating vulnerability in the portfolio amidst market fluctuations, which may affect investor confidence.
- Portfolio Adjustments: The strategy exited positions in Zai Lab, UniCredit, and Linde during the quarter while repurchasing EssilorLuxottica, Galderma Group, and Ryanair, demonstrating management's sensitivity to market dynamics and adaptability.
- New and Closed Positions: The fund initiated positions in Sandvik and Mettler-Toledo while closing several positions including Mitsubishi Heavy Industries, Givaudan, and Lenovo, reflecting a reassessment of future market opportunities.
- Sales Dynamics: Trane Technologies was among the larger sales in the portfolio, potentially indicating a cautious outlook on the company's future growth prospects, thereby influencing the overall direction of the investment strategy.
See More
